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ABSTRACT
Women are 8 times more likely than men to experience a urinary tract infection
(UTI) with up to 60% of women reporting a UTI in their lifetime. This significant
healthcare burden is caused by the infection of uropathogenic Escherichia coli (UPEC)
in the urinary tract resulting in clinical symptoms like urinary urgency, frequency, or
hematuria. If left untreated, UPEC can retrograde to the kidneys causing more serious
complications such as pyelonephritis. At this time, treatment is limited to antibiotic
therapy, which is challenged by antibiotic-resistance. These factors make UTIs an NIH
Women’s Health Initiative priority and are motivation for our research.
CgA (protein encoded by CHGA, located on chromosome 14) is a protein of the
granin family co-released with catecholamines from neuroendocrine cells throughout the
body. Pro-hormone convertases post-translationally cleave CgA into peptides, like
catestatin, which can have antimicrobial peptide (AMP) activity. Previous research
demonstrates CgA modulation of AMP activity in the skin. Additionally, systemic CHGA
knockout mice demonstrate increased bacterial load in a murine UTI model. Therefore,
our research aims to address CgA modulation of AMP and immune response in the
bladder during a UTI (cystitis). We demonstrate CgA’s ability to facilitate AMP release
from human bladder urothelial cells and explore the protein’s barrier function under the
murine UTI model.
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CHAPTER ONE
INTRODUCTION - LITERATURE REVIEW
Chromogranin A as Targeting Factor in Urinary Tract Infections
In the United States (US), Uropathogenic Escherichia coli (UPEC), a gramnegative uropathogen, is the leading cause of uncomplicated urinary tract infections
(UTIs) in women today [1]. Up to 60% of women will experience at least one UTI in their
lifetime costing the US over $3.5 billion per year [2, 3, 38]. The criteria for
uncomplicated UTI diagnosis is challenged in academia, but is currently defined by the
Center for Disease Control (CDC) as patients having at least one of the following
symptoms: fever (>38 C), suprapubic tenderness, costovertebral angle pain or
tenderness, urinary urgency, urinary frequency, or dysuria, and a bacterial count of ≥105
CFU/ml [4]. If left untreated, cystitis (infection in bladder) can retrograde to the kidneys
causing more serious complications, such as pyelonephritis. At this time, treatment is
limited to antibiotic therapy, which is challenged by antibiotic resistance. The necessity
for better prevention screenings and treatment methods makes this significant
healthcare burden an NIH Women’s Health Initiative.
During a UTI, UPEC is equipped with two key virulence factors – flagella and
type I pili [6]. Flagella allows UPEC to move against the urine flow, while type I pili
facilitate attachment to the mucosal surface of the urinary tract. The type I pili promote
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binding through the FimH cap, a mannose-binding adhesion protein. This versatile
virulence factor allows UPEC to bind the surface of urothelial cells (superficial layer
epithelial cells on bladder) with stability even under the shear stress of urinary flow [6,
13]. Once bound, UPEC invades the urothelium and activates the innate immune
system. One of the first line defenses of human innate immunity are oligopeptides called
antimicrobial peptides (AMPs). In eukaryotic epithelial cells, AMP production is induced
via toll-like receptors (TLRs) by invading pathogen molecules, like bacterial
lipopolysaccharide (LPS). Antibacterial AMPs are often amphipathic, with both
hydrophobic and hydrophilic domains, which allows them to target and disrupt the lipid
bilayer of the bacterial cell membrane [5]. Disruption of the AMP response has been
observed in the skin when neuroendocrine mediators, like chromogranin A (CgA), are
defected. Dampened AMP response results in increased bacterial invasion, and thus
has implications for success of UPEC in UTIs.
CgA (protein encoded by CHGA, located on chromosome 14) is a protein of the
granin family co-released with catecholamines from neuroendocrine cells (also termed
catecholaminergic cells) throughout the body in response to signals sensed by the
nervous system [6, 8, 9, 26]. The 48kDa protein is acidic in nature (due to the high
percentage of glutamic acid and aspartic acid in its structure), has catecholaminedependent aggregation properties, and several other factors, which are characteristic of
the granin family [7, 9]. It also binds calcium (Ca2+) at a high capacity, but moderate
affinity. An increase in Ca2+ signals exocytosis of CgA with other hormones from
secretory granules in the adrenal chromaffin cells and adrenergic neurons [8, 9, 19]. In
the secretory granules of islet cells, CgA blocks Ca 2+ influx in response to glucose,
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which inhibits the release of insulin [20]. In this sense, CgA can regulate glucose
homeostasis.
Various tumors can arise in the endocrine glands where CgA is produced. This
makes CgA an essential clinical marker of neuroendocrine tumors, elevated levels
indicating presence of tumor. In addition, abnormal levels also signify: inflammatory
bowel disease, Parkinson’s disease, hypertension, hand, foot, and mouth disease,
periodontitis, and stress [6]. As a current precursor for aforementioned disease states,
there is possibility that aberrant CgA could also indicate UTI or complicated UTIassociated disease, like pyelonephritis.
Chromogranin A and Catestatin
Pro-hormone convertases post-translationally cleave CgA into peptides:
vasostatin-1, vasostatin-2, pancreastatin, parastatin, and namely catestatin (CST) [7,
20]. The proteolytic cleavage products of CgA have several different functions in
maintaining immune and metabolic homeostasis [20]. CST is a 21-amino acid cationic,
hydrophobic peptide that is pleotropic [8]. It functions as part of a negative feedback
loop with potent inhibitory activity on nicotinic receptors, blocking catecholamine release
and thus release of its precursor, CgA. Clinically, patients with hypertension
demonstrate high levels of CgA and low levels of CST in the plasma, with an overall
hyperactivity observed in the sympathetic nervous system. This disease state, caused
by the dysfunctional negative feedback loop in relation to the nicotinic receptors, can be
rescued with a dose of CST [7]. Additionally, in CgA knockout (KO) mice, administration
of CST rescues hypertension as well [9].
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CST also has metabolic functions as it inhibits the 2-adrengeric receptor and
increases leptin signaling [8]. This increases the lysis of lipids in adipose tissue and
breakdown of fatty acids in the liver, providing the opposite effect of insulin on the body.
Demonstration of CST metabolic activity is seen in CgA-KO mice, who exhibit an obese
phenotype. After administration of CST, fat deposits decrease by ~25%. This has
implications on the weight gain observed in patients with inflammatory diseases (for
example, inflammatory bowel disease) and subsequently lower CST plasma levels [8].
Finally, CST plays a role in immunity [9]. As part of the innate immune response,
CST acts as an antimicrobial that can penetrate bacterial membranes to cause lysis of
the invading pathogen [8]. Beyond a direct effect on pathogens, CST is antiinflammatory in nature, especially in autoimmune diseases. In vivo colitis mouse model
studies demonstrated decreased granulocyte activity and circulating CRP, when the
mouse was treated with CST. Recruitment of macrophages and monocytes to the site of
infection also decreased with CST treatment. The mechanism of anti-inflammatory
activity observed by CST in vivo is unclear, but it is hypothesized that the peptide
affects the release of pro-inflammatory cytokines and chemokines [8]. Therefore,
impairment in the proteolytic cleavage of CgA downregulates the release of CST and
thus increases in disease states above.
CST may also play a role in determining the fate of a monocyte into a
macrophage. Although there was no correlation between the two, treatment of
monocytes with CST resulted in more anti-inflammatory phenotypes (M2 macrophages)
as compared to control. Namely, increased levels of mannose receptor-C type 1
(MRC1), anti-inflammatory macrophage marker, was observed [8]. MRC1, or CD206, is
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a transmembrane protein on the surface of macrophages that “recognizes mannose,
fucose, and N-acetylglucosamine sugar residues on the surface of microorganisms” [10,
12]. As part of the human innate immune system, MRC1 is a pattern recognition
receptor (PRR) that mediates endocytosis and phagocytosis of invading pathogens [11].
This has an interesting implication for UTIs. As UPEC invades the urothelium,
macrophages are recruited to the site of infection. MRC1 will recognize and
phagocytose UPEC, while at the same time, UPECs versatile virulence factor, type I pili,
will recognize mannose residues on the surface of macrophages. Knockout of MRC1
prevents uptake of non-pathogenic E. coli, emphasizing the importance of the type I pili
virulence factor [12]. As macrophages work to clear infection, UPEC attempts to evade
the harsh host environment (i.e. presence of antibiotics) by offering itself to
macrophages for hopeful survival inside the cell. Research demonstrates that fimbriated
UPEC increases macrophage adhesion and survival in the presence of antibiotics
compared to non-fimbriated mutants. Additionally, increase in dose of infecting UPEC
was directly proportional to pathogenic survival of phagocytosis [13].
CST maintains the balance of macrophages during inflammatory diseases, like
ulcerative colitis (UC) [14]. UC is an inflammatory bowel disease (IBD) that causes
inflammation of the inner lining of the large intestine (colon) and rectum. IBDs are
distinguished by a cycle of chronic relapse of inflammation and then remission. There is
currently no cure available for patients suffering from IBD, so treatment focuses on
supportive care during flare-ups and maintenance of remission. CgA has been indicated
as an important molecule in UC patients, with high CgA levels during periods of
inflammation. As previously discussed, CST has anti-inflammatory properties – acting in
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negative feedback loop to block release of CgA and also, macrophage polarization.
Using an acute and chronic murine model of UC, researchers have demonstrated
decreased release of IL-6, IL-1β, and TNF- α from M1 (pro-inflammatory) macrophages
when treated with CST. Although, CST was unable to promote release of antiinflammatory cytokines – IL-10 and TGF-β – from M2 (anti-inflammatory) macrophages.
M1 markers, inducible nitric oxide synthase (iNOS) and monocyte chemoattractant
protein-1 (Mcp1), were also downregulated in UC model after CST treatment [14].
CST also acts as an antimicrobial in the innate immune response. Therefore, it is
important to characterize how CST affects the gut microbiome during UC. Within the
murine chronic UC model, mice were treated with CST and stool samples were
collected for analysis. Treatment group showed no differentiation from untreated control
in bacterial diversity or abundance. Whereas, dextran sulfate sodium (DSS) – positive
control – showed significant altered microbial diversity [14].
Interestingly, CST demonstrates three single nucleotide polymorphisms:
Gly364Ser, Pro370Leu and Arg374Gln [49]. Gly364Ser and Arg374Gln have less
inhibitory activity on the catecholamines as compared to Pro370Leu or WT CST, and
about 4% of the population exhibits one of the polymorphisms. The varying degree of
catecholamine inhibition could alter the host defense response to infection, for example
in the instance of UTI. Additionally, given CgA’s role in barrier function during a UTI, it
begs the question of whether or not these genetic polymorphisms could alter host
susceptibility.
CgA is important part of host defense against invading microbes. The proteolytic
cleavage of CgA results in several products, namely CST. This peptide has several
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important functions in homeostasis of immunity. CST can block its precursor in part of a
negative feedback loop, increases lipid breakdown, has antimicrobial activity, and can
encourage the polarization of M2 anti-inflammatory macrophages. Each of these
functions contributes to the balance between inflammation and healing (antiinflammatory actions) during infection or disease states (like UC).
Chromogranin A as Diagnostic Marker in Disease
CgA is an important marker for a variety of diseases. As a neuroendocrine
peptide that is released with catecholamines during periods of stress, CgA has several
functions part of host defense. Its specificity ranges from neuroendocrine tumors,
neurodegenerative disorders, inflammatory disease, and viral and bacterial infections.
The following section will demonstrate the scope of CgA as a diagnostic marker.
Pancreatic Neuroendocrine Tumor (PNET)
Pancreatic neuroendocrine tumors (PNET) are a common type of
neuroendocrine tumor (NET) that develop in the pancreas [17, 18]. NETs arise in
endocrine glands and are characterized by their unique secretory granules, termed
large dense-core vesicles (LDCV), and production of hormones [18, 19]. The majority of
PNETs are malignant in nature, but severity can range from benign to remarkably lifethreatening. Mortality in PNET patients is often due to metastases to the liver and
subsequent liver failure. Two clinical presentations exist – functioning and nonfunctioning (NF-PNET) [18]. These are defined by their ability to cause hormonal
hypersecretion syndrome, but this can be difficult to diagnose as non-functioning often
evolves into functioning. Based on the hormones released into the bloodstream during
hypersecretion, patients can present with a variety of symptoms. The most common
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markers include abdominal pain, weight loss, feeling thirsty, urinary frequency, and
lethargy. In NF-PNETs, excess hormones are not released, which is why symptoms are
usually not present until the tumor grows large enough to notice or metastasizes to
other organs [22].
Understanding the severity of PNET and its functionality are essential
components for diagnosis and treatment strategy. Two approaches to PNET patients
exist – “wait and see” or aggressive treatment [17]. The latter requires specialists from
several different departments to collaborate and often is defined by surgical
management. CgA is a prominent marker in the diagnosis and management of PNETs.
Even if hormonal hypersecretion syndrome is not clinically present, measuring serum
levels of CgA assists in prevention of disease progression; in fact, the protein has 60100% diagnostic sensitivity [17, 18].
CgA enters through the endoplasmic reticulum of the cell and is carried by the
Golgi to be stored in the LDCV of PNETS. This allows CgA to be widespread throughout
the tumor tissue [20]. As a type 0 biomarker, defined by the NIH as “markers of the
natural history of a disease correlate longitudinally with known clinical indices
(symptoms) over the full range of a disease state,” increased CgA serum levels were
associated with diffuse disease state of NF-PNETs [20]. This simply means CgA was
especially increased in cases where PNET had metastasized to the liver. The
relationship between CgA serum levels and NET severity is unique to PNET specifically,
not all NET types exhibit this correlation or specificity.
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Small Cell Carcinoma of the Bladder (SCCB)
Small cell carcinoma of the bladder (SCCB) is an extremely rare neuroendocrine
tumor. Diagnosed late in the disease progression, SCCB is aggressive (highly
metastatic) and frequently difficult to identify. In fact, over 95% of cases are diagnosed
at muscle invasive stage and about 70% of patients die within the first 12 months of
diagnosis [21, 23]. Other than the presence of a tumor, the main symptoms are dysuria,
hematuria, and UTI. Histology and immunohistochemistry (IHC) of a tumor biopsy is
necessary for diagnosis. Haematoxylin and eosin (H&E) histological staining reveals the
same phenotypes seen in small cell lung carcinoma (SCLC), and thus the World Health
Organization (WHO) requirements for SCLC diagnosis are followed. The phenotype
includes densely packed cells with sparse cytoplasm and few organelles [21].
SCCB is very similar to invasive urothelial carcinoma, but it is more aggressive in
disease state and progression. This makes it critical to have a reliable marker(s) to
accurately differentiate between the two. CgA is one of the antibody markers used in
IHC and is present in ~60% of SCCB cases (range 20-89%) [23]. IHC staining with CgA
antibody on urothelial carcinoma samples is only ~5% [23]. A SCCB sample would
demonstrate strong, cytoplasmic staining of CgA, as well as a few other antigens like
synaptophysin and neuron-specific enolase [23].
Parkinson’s Disease (PD)
Parkinson’s Disease (PD) is a neurodegenerative disorder that causes motor
dysfunction in its patients [24, 25]. The motor deficits are caused by degradation and
subsequent loss of function of dopaminergic neurons. These neurons are located in the
midbrain, specifically in the substantia nigra pars compacta (SNpc). As the name
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suggests, dopaminergic neurons are responsible for dopamine (DA) production and
release [26]. Symptoms of PD include “tremor, bradykinesia (slow movement), muscle
rigidity,” and “impaired gait and posture” [25]. Additional defects are frontostriatalmediated and include dysfunction in “attention, speed of mental processing, verbal
disturbances, impairment of working memory and impulsivity” [25]. Albeit the cause of
PD is debated, it is likely due to misfolded proteins that clog up the cytoplasm of
dopaminergic neurons.
CgA serum levels are widely used as a marker in other neurodegenerative
diseases, like Alzheimer’s [27]. In the case of PD, the overall loss of function in the
midbrain results in the breakdown of dopaminergic neurons – which are a type of
catecholaminergic cell. As previously discussed, CgA is produced and released from
the secretory granules of catecholaminergic cells. Hence, as the dopaminergic neurons
lose function and degrade, CgA is not produced and released. The decreased CgA
levels are reflected in cerebral spinal fluid of PD patients [27]. This correlation is rather
new (January 2021) and additional studies need to be conducted to confirm the use of
CgA as a diagnostic marker of PD.
Hypertension (HTN)
Hypertension (HTN) is a chronic increase in blood pressure associated with age
and influenced by genetic and environmental factors [28]. Individuals with HTN are at an
increased risk for other cardiovascular disease as the two are linked to one another. In
order to reach an HTN diagnosis, a patient must have increased blood pressure for at
least two consecutive clinic visits, target organ damage (impairments of major organs
caused by increased blood pressure), and/or evidence of cardiovascular risk factors
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(like age). White-coat HTN – caused by a patient’s discomfort in the medical setting or
with the physician – has proved to be a precarious complication. It is now controlled for
by assessing ambulatory blood pressure, which will stay constitutively increased in
patients with true HTN, while paralleling normotensive pressure for white-coat HTN
patients [28].
Disruption in sodium and fluid homeostasis is the likely first step in HTN
development. The balance of sodium and fluids is highly regulated in the kidneys, and is
controlled throughout the body by “hormonal, nervous system, paracrine, and
intracellular feedback loops” [28]. When the kidney has difficulties maintaining normal
fluid volumes, blood pressure increases. One role of CST, as described prior, is a
negative feedback loop blocking catecholamine release and thus its precursor, CgA [7].
In hypertensive patients, CgA serum levels are elevated, while CST is depleted. This
indicates a dysfunctional negative feedback loop between CST and the nicotinic
receptors that control catecholamine release, which can be rescued with administration
of CST [7, 29]. Sodium dyshomeostasis observed in the kidneys causing HTN, is likely
due to the hormone imbalance occurring throughout the body as the negative feedback
loop is nonfunctioning [28, 29]. Although CgA is not currently used as a diagnostic
marker for HTN, it does play a role in progression of the disease state.
Pediatric Hand, Foot, and Mouth Disease (HFMD)
Hand, foot, and mouth disease (HFMD) is an infection caused by enteroviruses –
coxsackievirus A16, coxsackievirus A6, or enterovirus 71 (EV-A71). HFMD spreads
easily in children under the age of five, outbreaks often occurring in day cares. The virus
is transmitted through respiratory droplets in the air or on fomites. Symptoms include
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fever, mouth sores, and sore throat, with the signature symptom appearing as a rash on
the palms of the hands or soles of the feet. Although contagious, the disease state is
often non-severe [15]. If infected with EV-A71, complications are more common and a
simple infection can rapidly decline into central nervous system (CNS) injury (brainstem
encephalitis), neurogenic pulmonary edema (NPE), or pulmonary hemorrhage, which
can lead to death [16].
HFMD is endemic in China and South East Asia and there is currently not a
stable treatment or indicator to prevent the more severe disease state [15, 16]. Since
CgA is a neuroendocrine mediator, alterations in serum levels coincide with sympathetic
nervous system status. Patients with severe HFMD have hyper-active sympathetic
nervous systems with onset of symptoms that complicate into CNS injury or NPE.
Research supports the use of CgA as a diagnostic marker for severe HFMD. In a study
done on pediatric patients with EV-A71 HFMD, increased CgA serum levels on
presentation was directly associated with mortality [16].
Periodontitis
Periodontitis is an inflammatory disease caused by pathogenic bacterial buildup
and biofilm formation that degrades the gums supporting teeth [30]. Treponema
denticola and Porphyromonas gingivalis are the two anaerobic bacteria, which
frequently cause periodontitis [31]. In the response to bacterial infection, the inflamed
gums pull away from the teeth causing bleeding [30]. Patients suffering from
periodontitis are typically those who are not able to practice proper oral hygiene or who
do not have access to regular dental care. These stressors can exacerbate the
periodontal symptoms. If the infection progresses, the patient can lose teeth and painful
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abscesses can form. Psychological stress as determined by salivary cortisol levels is
associated with periodontal infection. Stress exhausts the immune response allowing an
easier pathway to infection for bacteria [31].
Salivary CgA levels are rather sensitive to environmental stressors (dry mouth),
as well as immune stressors (microbial infection). This makes CgA a particularly
delicate predictor for periodontitis as compared to cortisol. While cortisol is useful for
assessing the advancement of periodontitis, the caveat remains its inability to predict
disease. As the inflammatory response is activated in the oral cavity in response to
stress or infection, neuroendocrine mediators (like CgA) are released to facilitate host
defense. The source of CgA is likely accredited to the human oral mucosa, similar to
other mucosal surfaces throughout the body. The release of CgA in periodontal infection
is specific, with increased levels identified in saliva, but not serum [31].
Antimicrobial Peptides
The human immune response is divided between innate and adaptive immunity.
Innate immunity is the first line of defense against invading pathogens. While adaptive
immunity constitutes a more sustained response in host defense. When the body is
threatened by a bacterial, viral, or fungal invasion, AMPs are the first line of protection.
Their antimicrobial activity allows them to target and kill the foreign microbes, similar to
the actions of antibiotics [32]. The most compelling advantage of AMPs are their
antibiotic activity on antibiotic-resistant strains of bacteria. Their ability to target not only
bacteria, but also fungi and viruses also gives them an added benefit compared to
traditional antibiotics. Understanding the full scope of AMPs is important for researchers
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and clinicians alike, but in this review a focus will be placed on AMP activity in regards
to bacteria, specifically gram-negative.
AMPs are mostly cationic and amphiphilic, which enables them to disrupt
bacterial structures efficiently [32]. The positively-charged AMPs are rich in lysine and
arginine (positively charged amino acids). This positivity creates an electrostatic
interaction between the AMP and the negative cell membrane of bacteria. Their
hydrophilicity and hydrophobicity allow the AMP to breach the lipid bilayer, and take root
in the hydrophobic core of the inner membrane. AMP activity is not restricted to gram
positive or gram negative bacteria, instead they are able to agitate either cell structure
successfully [32]. Mammalian cationic AMPs can be divided based structure – -helical
peptides and β-sheet peptides – or by biological properties – cathelicidins and defensins
[32].
Cathelicidins
Cathelicidins are composed of two functional domains. Cathelin at the N-terminal
and an antimicrobial domain at the C-terminal [34]. Although thousands of cathelicidins
exist in mammals, only one is present in humans – LL-37 (sometimes termed CAMP),
encoded by the gene CAMP. LL-37 is an -helical AMP and derives its name from its
37-amino acid length [35]. During early discovery, LL-37 was thought to be stored only
in myeloid cells – like neutrophils or macrophages, but later it was determined it also
resides in alternative cell types, like epithelial cells [34]. Now it is widely accepted that
LL-37 is present in an array of tissues, from the gastrointestinal tract to the squamous
epithelium of the tongue [34, 35]. Interestingly, prior to the discovery of antibiotics,
patients infected with Mycobacterium tuberculosis had improvement after spending
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extended periods in the sun. Therefore, “sun baths” were prescribed to those infected
[34]. This is likely due to the activation of LL-37 in macrophages in response to vitamin
D release in the skin by sunlight. The increase in sunlight exposure increased LL-37
availability to response to Mycobacterium tuberculosis.
Activation of LL-37 is initiated by proteolytic cleavage into its two regions –
cathelin (highly conserved) and antimicrobial domain [34]. In the activated form, they
are released from secretory granules in part of the inflammatory response and/or
infection. As a cationic peptide, cathelicidin AMP domain can specifically target the
negatively charged membrane of microbes. In the example of gram-negative bacteria,
like UPEC, the AMP binds parallel to the outer membrane, adheres, and perpendicularly
slinters itself into the periplasm until finally crossing the inner membrane. This splinter
allows access for other AMPs to enter and coagulate together in the cytoplasm. These
actions ultimately kill the bacterial cell [34].
Defensins
Defensins are comprised of β-sheet peptides, connected by disulfide bonds [36].
Based on the location of the disulfide linkages, defensins are further categorized in
humans into α- and β-defensins. The category of defensin also determines the location
of its storage. α-defensins are localized to neutrophils, while β-defensins are a part of
the epithelia throughout the body. During the innate immune response, defensins are
either released from neutrophils, or from surrounding epithelial tissue [36]. During a UTI,
defensins are released from the urothelial cells that line in inside of the bladder. Their
activation is achieved through post-translational modifications [36].
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Human β-defensins (HBD) 1-4 are the best studied of the HBDs and are found
mostly in epithelial tissues. They can be constitutively expressed, or activated in
response to bacterial infection via TLR stimulation or pro-inflammatory cytokines. Less
is known about human α-defensin activation, but it is likely due to pro-inflammatory
cytokines as well [36]. Each of the HBDs are differentially effective in bacterial cell
disruption, but all can efficiently act as part of host defense. Once the an HBD reaches
the bacterial invader, their actions are similar to that of cathelicidins. Simply, they are
able to disrupt the bacterial membranes and initiate cell death [34, 36]. Human
defensins, α and β alike, are also important for the modulation of the inflammatory
response. They assist in the release of cytokines and chemokines, while also
influencing the apoptosis of neutrophils based on environmental cues [36].
Microbiota of the Urinary Tract
Albeit academia has debated the presence of the female urinary microbiome,
research has confirmed its existence [37]. The most up-to-date study projects over 100
different species that contribute to the female urinary tract (UT) and urogenital tract
(UGT). The lower UT (bladder and urethra) is comprised of urothelial cells, whose
luminal side is covered by a glycosaminoglycan (GAG) layer and apical side with
umbrella cells [38]. Umbrella cells of the apical urothelium express transmembrane
uroplakins, which are plaque-forming proteins. These special plaques make it difficult
for foreign microbes to attach and invade the urothelium. They also are flexible to
accommodate micturition (emptying and filling) of the bladder. Although it is now agreed
that a UT microbiome exists, the location of these commensal bacterium is still
unknown. It is possible that, like UPEC’s attachment due to virulent type I pili, they also
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are able to attach to uroplakins [38]. The exact composition of the UT microbiome is
also complicated. The bladder, in example, is a dynamic environment. The pH of urine
varies, the bladder fills and expels, there is shear flow, immune involvement, and the
issue of a reliable nutrient source. It could be that a urine-full bladder provides nutrients
for the host microbiome or, conversely, perhaps the commensals breakdown and utilize
the GAGs covering the urothelium [38]. Further research is needed to understand both
the location and mechanism of survival of the UT microbiome.
16s rRNA sequencing is regularly used in the field to determine the players of the
UT microbiome [37, 38]. The 16s gene is highly conserved across all DNA-based life
forms. Therefore, universal primers of 16s conserved regions can be amplified via PCR
encompassing all microorganisms present in the sample. This, along with enhanced
quantitative urine culture (EQUC), which allows for differential culturing of the sample,
provides researchers with a comprehensive picture of the microbiome. In current
literature, the composition of the UT commensal population is varied, but the major
genera include: Lactobacillus, Corynebacterium, Prevotella, Staphylococcus, and
Streptococcus [38]. Additionally, the female microbiome of the UT does share
characteristics with the vaginal microbiome, which is supported based on the proximity
of the urethra to the vagina. Lactobacillus is known to be prevalent in the vaginal
microbiome and the UT shares this commensal prevalence. Further research is
necessary to determine the environment of the female UT and UGT. Understanding and
characterizing the microbiome will reveal the full interactions between invasive species
and the UT during disease states, like UTI.
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Concluding Remarks
An uncomplicated UTI is diagnosed based on a bacterial count of ≥105 CFU/ml.
This arbitrary threshold was determined years before a UT microbiome was discovered
and accepted. Currently, there is a disconnect between academia and the clinic, where
asymptomatic patients may be treated for a UTI based on a positive urine culture. This
does not take into account the presence of bacterial species in the natural female
microbiome and contributes to antibiotic over-use.
When UPEC invades the UT, it is equipped with unique virulence factors – type I
pili and flagella – that allow it to survive in the harsh environment and evade the
immune system. On the host side, uroplakins of the umbrella cells express CgA, a
diverse disease marker, whose proteolytic cleavage products – namely CST – can
recruit macrophages, have AMP activity, and/or work in the negative feedback loop for
CgA suppression. The AMPs are responsible for targeting and destroying bacterial
cells, while also modulating the innate immune response through cytokines and
chemokines or induction of immune cell apoptosis.
In literature, abnormal production of CgA and its products results in detrimental
dysfunction in a variety of disease states. This is especially true when CST is not
present to regulate the negative feedback loop. There is value in understanding the role
of CgA and CST in the context of UTI, especially appreciating the part CgA plays in
other PNET, SCCB, and other bacterial infections, like periodontitis. In order to address
the relationship between CgA and cystitis, we set up two aims:
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AIM 1: Reveal mechanisms by which altered production of CgA/CST
modulates TLR-dependent AMP activity and immune responses in human
bladder epithelial cells.
a. Assess CHGA-depleted modulation of AMP responses and
cytokine/chemokine secretion in WT and siRNA knockdown cells
AIM 2: Establish that CHGA modulates the local bladder AMP and innate
immune response to UPEC infection in mice.
b. Quantify AMP responses, cytokine/chemokine production and immune cell
infiltration in WT and uro-CHGA-/- mice.
c. Quantify UPEC survival, attachment and invasion in WT and uro-CHGA-/mice.

CHAPTER TWO
MATERIALS AND METHODS
In vitro – AIM 1
siRNA
In order to assess CgA-depletion on AMP responses and cytokine/chemokine
responses, siRNA was done to knockdown CgA. Human bladder epithelial primary cells
(HBlEpC) (Cell Applications#938-05a) were cultured from a fresh P0 cryovial. Cells
were split at 100% confluency and plated on 12-well plates in Human Bladder Epithelial
Growth Medium (Cell Applications#217-500). At ~80% confluency, plates were ready for
siRNA transfection using the CHGA 27mer siRNA duplex kit (OriGene
Technologies#SR319699). One hour prior to transfection, plates were aspirated and
replaced with fresh media. From the 20uM company stock, siRNA and scrambled
duplex constructs were each combined with duplex buffer to reach 5uM concentration.
The 5uM mixes were then diluted again with transfection buffer and transfection reagent
– siTRAN (OriGene Technologies# TT320002) – for a final concentration of 5nM. Mixes
were incubated for 15 minutes at room temperature (RT), then were added dropwise to
respective wells while swirling. Plates were incubated for 8 hours at 37 C, at which point
were aspirated and replaced with fresh media to return to 37 C. After 24 hours,
supernatant was collected and set aside for lactate dehydrogenase (LDH) assay to
determine cytotoxicity. Then, cells were stimulated with vehicle control, 10ug/ml
20
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polyinosinic-polycytidylic acid (poly I:C) TLR control, 10ug/ml LPS, or 100ng/ml flagellin
and returned to 37 C.
Collection occurred 24 hours later (48 hours post-siRNA transfection). Cells were
lysed with TRIzol® reagent (Life technology#15596018) for 1 hour, following
manufacturer’s protocol, before scrapping. Purelink minikit (Fisher Scientific#12-183025) was used to isolate RNA. Complementary DNA was synthesized using iScript™
cDNA Synthesis Kit (Bio Rad#170-891).
Quantitative Polymerase Chain Reaction (qPCR)
Quantitative real time RT-PCR was performed in duplicate using TaqMan®
Advanced PCR Master Mix (Fisher Scientific# 44-445-56) on a StepOnePlus™ RealTime PCR System (Life technology) to determine the relative mRNA expression of
AMPs. Fluorogenic probe and primers were used to detect CHGA (Hs00900370_m1),
IL-6 (number), CAMP (number), TNF- (number), and DEFB4B (number). Expression of
target gene was normalized with B2M (4325797) and analyzed by the 2-ΔΔCt method.
LDH Assay
Supernatants were reserved from siRNA-transfected cells at 24hr, 48hr, or 72hr
to use with the cytotoxicity detection kit (LDH) (Roche#11644793001). Supernatants
were spun at 250xg for 10 minutes. 100uL/well of supernatant was transferred into a 96well plate. Reaction mixture was added and the plate was incubated for 30 minutes at
RT. Absorbance was measured at 492nm on Spectramax Plus 384 (Molecular Devices)
plate reader.
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Western Blot
Although qPCR enables measurement of relative gene expression, it does not
confirm the associated protein is produced. Therefore, a western blot was used to
confirm protein production of CgA, Il-6, cathelicidin, TNF- , and human -defensin 2.
Following the above siRNA protocol, 6-well plates were transfected to knockdown
CHGA. At 48 hours, cells were aspirated and RIPA buffer (Fisher Scientific#0089900)
with Protease Inhibitor cocktail (Fisher Scientific#78410) was added. While on ice, cells
were scraped into 1.5 mL tubes, spun down, and supernatants were reserved. Using
the Pierce™ BCA Protein Assay Kit (Fisher Scientific#23225), protein concentration
was confirmed to meet 30ug needed for SDS-PAGE (sodium dodecyl sulfate–
polyacrylamide gel electrophoresis). Samples were run for 21 minutes at 200V on a
NuPAGE™ gel (Fisher Scientific#NP0321BOX) in 20x MES SDS running buffer. Gel
was transferred using an iBlot™ 2 Gel Transfer Device (ThermoFisher#IB21001). After
washing and blocking, membrane was incubated with 1:1000 rabbit polyclonal
chromogranin A primary antibody (abcam#ab45179) overnight. The following day after
washes, the membrane was incubated with anti-rabbit IgG HRP-conjugated secondary
antibody (Cell Signaling Technology#7074S) before imaging. CgA bands appear at
~50.7kDa.
Enzyme-Linked Immunosorbent Assay (ELISA)
To assess the immune response through release of AMPs, a human cathelicidin
antimicrobial peptide (CAMP) ELISA kit was obtained (MyBioSource#MBS451986).
Supernatants were collected from triplicate treatments of siRNA transfection cells with
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TLR ligands (previously described). Eight standard serial dilutions were prepared
according to kit protocol, from 10ng/mL to 0ng/mL. Standards, blanks, and samples
were added to the pre-coated plate and allowed to incubate for 2 hours at 37 C.
Samples were added at 1:1 and 1:2 dilution to ensure a measurable result. After
incubation, plate was aspirated and the first detection reagent was added for 1 hour at
37 C. After this incubation, the plate was washed three times, the second detection
reagent was added, and the plate incubated for 1 hour at 37 C. After 5 more washes,
the substrate solution was added and the plate incubated for 15 minutes at 37 C. After
this final incubation, stop substrate was added and plate was run at 450nm on the
Spectramax Plus 384 (Molecular Devices) plate reader.
In vivo – AIM2
Murine Model of UTI
E. coli UTI89-vsfGFP-9 chromosomal strain of UPEC was streaked on a Luria
broth (LB) plate on day one. This UPEC GFP variant was optimized to eliminate any in
vivo virulent defects and is 10x brighter, which makes it a good choice for the murine
UTI model [40]. On day two, one colony was suspended in LB broth and set to incubate
statically in 37 C overnight. This incubation method allows for the UPEC to express
sufficient type-I piliation [39]. The following day, day three, a serial dilution of the
suspension was done to ensure type-I pili are expressed in majority of bacteria [39]. On
day four, infection day, the suspension underwent a series of spins and washes before
being measured at OD600 to confirm ~2x107 CFU.
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Mice with CHGA knocked out in uroplakin II of bladder urothelium (uro-CHGA-/-)
were obtained from crossing CHGAflox- mice (developed by Mutant Mouse Resource and
Research Center at University of California Davis) with UPKII-Cre mice. A catheter,
made from 30-gauge needle and polyethylene tubing, was used to infect Uro-CHGA-/and wild type (WT) C57BL/6 mice intraurethrally with 10uL ~2x107 CFU UPEC over 10
seconds following the murine model of UTI [39]. Bladders, kidneys, and/or spleen were
harvested 6 hours or 18 hours post-infection. Kidneys were reserved for bacterial
counts. Bladders were also taken for bacterial counts, as well as qPCR,
immunohistochemistry (IHC), terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) staining, and electron microscopy (EM). Spleen was used as control
cell population in FACS.
Genotyping. In order to confirm proper genotyping of the mice, tail snips were
taken from the experimental group prior to day of experiment. They were digested in
Direct Tail PCR reagent (Viagen#101-T) and Proteinase K 10mg/ml (Sigma#P6556) for
3 hours at 55 C. Then heat was increased to 85 C for 45 minutes. Samples were
vortexed and used for PCR. Reactions included DreamTaq™ Hot Start Green PCR
Master Mix (ThermoScientific#K9021), CHGA forward and reverse primers, and
molecular grade water. Each reaction included CHGA floxed forward primer
(TAGTGGGCAGAGTGTTTTGCATTGG) and one of the two reverse primers:
(AGTCAAATCACATGGGCATTCCAGC or ATCTGCTCTGTGTTTATCGGCAAGC).
Reactions were run on Eppendorf Mastercycler PRO S6325 thermal cycler. Samples
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were run on a 1% agarose gel 1x TAE (tris-activated EDTA) (ThermoScientific#B49) for
45 minutes at 100V. Gel was viewed and imaged on a Bio Rad ChemiDoc XRS+.
qPCR. In order to confirm uro-CHGA-/- via relative gene expression, qPCR was
done. To prepare excised bladders for qPCR, samples were added to 1mL of TRIzol ®
reagent (Life technology#15596018). In a cryogenic grinder (SPEX®
SamplePrep#6770), which uses a magnetic impactor at liquid nitrogen temperatures,
samples were pulverized into powder and allowed to melt at room temperature for RNA
isolation. The above protocol was followed. Fluorogenic probe and primers were used to
detect CHGA (Hs00900370_m1). Expression of target gene was normalized with
GAPDH (0912025) and analyzed by the 2-ΔΔCt method.
Bacterial count. Bacterial counts were taken to compare bacterial load by strain
and ascertain presence of ascending infection or reflux into the kidneys. Kidneys and
bladders were homogenized in 1mL phosphate buffered saline (PBS) with chrome-steel
beads (BioSpec#11079113c) on a BioSpec Mini-Beadbeater (BS#607). Homogenates
were 10-fold serially diluted in PBS and plated on LB agar plates. These plates were
incubated for 24 hours at 37 C and then counts were taken.
Immunohistochemistry Staining (IHC)
IHC allows visualization of bladder morphology through H&E, provides
confirmation of Uro-CHGA-/- via double stain, and indicates apoptosis as a result of
bacterial invasion by TUNEL stain. For these purposes, bladders were excised and
placed directly into a 15mm base mold with cryo optimum cutting temperature (OCT)
compound (Fisher Scientific# 14-373-65). After setting for ~5 minutes, base molds were

26
frozen in liquid nitrogen for 20 seconds to reach solidification. Sectioning was done in
house on a CryoStar NX50 (Thermo Scientific) cryostat or sent out to Loyola Clinical
Pathology Lab. Both 14um and 5um sections were taken from the center of the bladder
and situated on slides.
H&E staining. Slides were dried in hybridization oven at 60 C for 15 minutes. A
standard H&E staining protocol was followed. Hematoxylin Solution, Harris Modified
(Millipore Sigma#HHS80-2.5L) and Eosin Y solution, alcoholic (Millipore
Sigma#HT110180-2.5L) were used. Slides were fixed with VectaMount® Permanent
Mounting Medium (Vector Laboratories#H-5000-60). Staining was viewed on an
EVOS® FL Cell Imaging System from Thermo Fisher Scientific at 40x (data not shown).
Co-localization stain. Frozen slides were removed from -80 C and allowed to
air dry. A hydrophobic barrier was drawn around the samples with a PAP pen (Vector
Laboratories#H-4000). Slides were fixed with ice cold methanol and washed 3x with
PBS. They were incubated with blocking buffer – 10% normal goat serum, 1% bovine
serum albumin, 0.5% Triton X-100 in 0.1M phosphate buffer, pH 7.4 – for one hour at
RT. Primary antibodies – anti-CHGA unconjugated (Abcam#ab254322) and antiuroplakin II unconjugated (Abcam#ab204756) – were added with 3% normal goat
serum, 1% bovine serum albumin, 0.5% Triton X-100 in 0.1M phosphate buffer, pH 7.4
and left to incubate overnight at 4 C. The following day, slides were washed 3x with
cold PBS. The secondary antibodies – AF594 (Abcam#ab150080) and AF488
(Abcam#ab150077) – at a 1:2000 dilution were added to 3% normal goat serum, 1%
bovine serum albumin, 0.5% Triton X-100 in 0.1M Phosphate buffer, pH 7.4. Slides
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were fixed with ProLong™ Diamond Antifade Mountant with DAPI (Molecular
Probes#P36966). They were viewed under a widefield microscope at 60x.
TUNEL stain. During a UTI, urothelial cells undergo apoptosis as apart of
abnormal barrier function, in this case the absence of CHGA [42]. Therefore, bladders
were also cyro-sectioned by our pathology core at 14um and sent to receive TUNEL
stain from our collaborator, Dr. David Klumpp, at Northwestern University. Briefly,
TUNEL staining is able to identify cells that have undergone apoptosis through the
apoptotic hallmark, internucleosomal DNA fragmentation [41]. When the DNA
fragments, free 3'-hydroxyl termini become available. The TUNEL stain uses terminal
deoxynucleotidyl transferase to attach a labeled dUTP. In order to confirm specificity for
cells expressing uroplakin (where CHGA is depleted), tissue sections were pre-stained
with uroplakin Ia antibody (Novus Biologicals#NBP2-14694) prior to the TUNEL assay.
Then, they were treated with proteases before undergoing the TUNEL reaction. Finally,
they were fluorescent-FITC stained, followed by a counterstain, and viewed under a
fluorescent microscope [41].

CHAPTER THREE
RESULTS
In the context of the skin, CgA depletion results in dampened AMP and immune
response (cytokine/chemokine production and immune cell recruitment) [46]. This
abnormality in barrier function provides invading pathogens with a more hospitable
environment for infection. We hypothesized that CgA depletion in the urothelial cells of
the bladder could alter barrier function and modulate TLR-dependent AMP activity and
immune responses.
CHGA Modulation of AMP and Immune Response in Human Cell Line
In order to determine the role of CgA in vitro, we began by knocking down CHGA
via siRNA in human bladder epithelial cells (HBlEpCs). Preliminary optimization was
performed to determine the best concentration and duplex of siRNA (three provided by
company – A, B, and C). We concluded 5nM siRNA C was the most efficient
concentration and construct for transfection. The 24hr, 48hr, and 72hr collection
timepoints are shown demonstrating successful (at least 30% decrease) CHGA
knockdown compared to mock control maintained through 72hrs (n=4) (Figure 1a-c). A
lactate dehydrogenase (LDH) assay was performed to confirm knockdown was not a
result of cell cytoxicity (Figure 1d-e).
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Albeit qPCR can confirm CHGA depletion through relative gene expression in the
HBlEpCs, this is not indicative of protein production. Therefore, cell samples in
replicates of two were reserved at 24 hours and 48 hours post-siRNA transfection. The
treatment groups included untreated, mock treated, scrambled 5nM, and siRNA 5nM. A
western blot for CgA was performed, with B2M as control. Protein depletion is
appreciated at 48hr post infection.
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To understand the role of CgA in AMP modulation in the context of a UTI, toll-like
receptors (TLR) 4 and 5 were stimulated with LPS and flagellin, respectively, to parallel
the antimicrobial response elicited by UPEC; as they are found on the surface of E. coli.
HBlEpCs were separated into three treatment groups – mock treated, scrambled 5nM,
or siRNA 5nM – and transfected with siRNA for 8 hours. 24 hours post-transfection,
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samples were stimulated in replicates of three with vehicle, 1000ng/ml flagellin (TLR5
ligand), 10ug/ml LPS (TLR4 ligand), or 10ug/ml poly I:C (TLR control). Cells were
collected 48 hours post-siRNA transfection. qPCR was done for several AMP-encoding
genes including tumor necrosis factor (TNF), human beta defensin 2 (DEFB4B),
interleukin-6 (IL-6), or cathelicidin antimicrobial peptide (CAMP). Ct values were
analyzed by the 2-ΔΔCt method. CHGA knockdown induced TNF expression under
treatment with flagellin compared to scrambled treatment (unpaired t test p=0.0487)
(Figure 3a). Also when treated with flagellin, CHGA knockdown decreased DEFB4B
expression (unpaired t test p=0.0026) (Figure 3c). Literature supports the barrier
function of DEFB4B in mucosal immunity of the urinary tract during E. coli infection [43].
CHGA-mediated DEFB4B response to flagellin could have important implications for
understanding the mechanism of AMP-mediated immune responses during UTI. There
was no change appreciated in IL-6 or CAMP expression across all treatment groups.
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In order to further understand this relationship, and to quantify AMP secretion
from cells after TLR stimulation, a human beta defensin 2 (hBD2) ELISA was done.
Supernatants were reserved at 48 hours from cells that had been transfected with
siRNA and undergone TLR stimulation. Three replicates for each treatment group –
mock treated, scrambled 5nM, or siRNA 5nM – stimulated with vehicle, LPS, flagellin, or
poly I:C were run against kit standards. There was no significant induction of hBD2
appreciated across three treatment groups, regardless of TLR stimulant (Figure 4d-f).
We do, however, appreciate in the presence of flagellin, that there was a dampened
defensin secretion as compared to vehicle in our siRNA 5nM treated cells (Figure 4d).
Although there was no relationship between CHGA depletion and CAMP on our
qPCR, literature emphasizes the importance of human cathelicidins in bladder host
defense against microbes [44]. Therefore, we decided to conduct a CAMP ELISA using
the above noted samples. There was no significant induction of CAMP appreciated
across three treatment groups, regardless of TLR stimulant (Figure 4a-c).
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CHGA Modulation of AMP and Immune Response in Mouse Bladder
Prior studies revealed a CHGA phenotype in mice during infection with UPEC.
Within the context of the murine model of UTI, CHGA-/- (systemic knockout) mice
demonstrated 40x higher bacterial load compared to WT (Figure 5a). Therefore, it was
appropriate to develop a tissue-specific knockout of CHGA in the urothelium to establish
that CHGA modulates the local bladder AMP and innate immune response to UPEC
infection in mice. Mice with CHGA floxed were crossed with uroplakin II Cre mice. This
provided knockout of CHGA in uroplakin II of the bladder urothelium (Figure 6a). In
order to confirm this genotype, tail snips were acquired from mouse pups for digestion
and PCR. Uro-CHGA-/- are Cre+ and match CHGA flox homozygous Cre+ bands in
reactions one and two (Figure 6b). Cre- mice indicate unsuccessful crossing and appear
without a band in reaction two, matching WT control (Figure 6b).
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Visualization of uro-CHGA-/- phenotype was achieved through co-localization
staining of the urothelium. Bladders were harvested from Cre+, Cre-, and WT mice and
maintained in OCT. 14uM sections underwent co-localization stain for CgA and
uroplakin II (UPKII). Slides were viewed under a widefield microscope at 60x. CgA
appears more diffuse in Cre+ strain compared to Cre- and WT, which demonstrate
punctate CgA staining along the outer urothelium (Figure 7a-i).
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Finally, relative CHGA expression of mouse strains WT, systemic CHGA
knockout, Cre, and Cre+ (uro-CHGA-/-) were measured via qPCR. Bladders were
harvested and placed in 1mL of Trizol. Samples underwent cryogenic grinding in
preparation for RNA isolation and subsequent qPCR. Fluorogenic probe and primers
were used to detect CHGA (Hs00900370_m1). Expression of target gene was
normalized with GAPDH (0912025) and analyzed by the 2-ΔΔCt method (Figure 8).

An important aim in this study was to quantify UPEC survival between our
strains. Bladders and kidneys harvested from uro-CHGA-/- and wild type (WT) C57BL/6
mice – 18 hours after infection with 10uL ~2x107 CFU UPEC following the murine model
of UTI – were homogenized and plated to assess bacterial count. Quantification of
UPEC after intraurethral inoculation revealed decreased CFU in uro-CHGA-/- bladders
as compared to WT (two-tailed unpaired Mann-Whitney test p=0.4) (Figure 9a).
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This relationship was also demonstrated in the kidneys (two-tailed unpaired MannWhitney test p<0.02) (Figure 9b). Results were repeated under the same conditions in
the bladder (two-tailed unpaired Mann-Whitney test, p<0.05) and the kidneys
(two-tailed unpaired Mann-Whitney test p<0.01) (Figure 9c-d). Reflux of bacteria into the
kidney may have been due to volume of UPEC injected (50uL), therefore, subsequent
studies decreased infection volume to 10uL [39]. Overall, this decreased UPEC survival
strays from the phenotype noticed under systemic CHGA knockout, where bacterial
growth was increased upon CHGA depletion (Figure 5). Therefore, this relationship
needs to be further investigated.
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CHAPTER FOUR
DISCUSSION
Urinary tract infections are a significant healthcare burden in the United States,
especially in females. Not only do they cost roughly $3.5 billion dollars per year, but
they are also becoming increasingly difficult to treat with the rise in antibiotic resistance.
Additionally, little is known about the microbiome of the urinary tract, whose existence
has only been accepted in academia within the last few years. There still remains a gap
between what is known in research and what constitutes as a UTI diagnosis in the
clinic. This is especially due to the arbitrary threshold of ≥105 CFU/ml bacterial count
that was set in the 1950’s and is still used today to diagnose UTIs. This threshold
disservices asymptomatic patients who surpass count and are treated with antibiotics
without a disease state, as well as symptomatic patients who do not meet 105 CFU/ml
and go untreated.
Characterizing host-pathogen interactions at the urothelium of the urinary tract is
an important first step in better understanding the microbial environment of the bladder.
Chromogranin A is a neuroendocrine mediator whose proteolytic cleavage product,
catestatin, induces AMPs, has antimicrobial activity, promotes M2 (anti-inflammatory)
macrophages, and regulates CgA production through a negative feedback loop. In
previous studies involving CHGA knockout in the skin, modulated AMP response to
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injury [46]. When looking at the

CHGA-/-

(systemic knockout) mice, CFU/ml after UTI

increased compared to WT. The data discussed here depicts a novel interaction
between host defense and invading microbes during urinary tract infection.
Chromogranin A is mediating some mechanism within UPEC invasion, as is
demonstrated by our bacterial counts, confirmed uro-CHGA-/- genotype, and increased
CAMP production.
Defensins and TNF During Urinary Tract Infections
In the context of the urinary tract, human beta defensin 2, gene DEFB4B, human
is an antimicrobial peptide important in cytokine and chemokine production and
maintenance of UT integrity [43]. As previously discussed, during a UTI, defensins are
released from the urothelial cells that line in inside of the bladder. Their activation is
achieved through post-translational modifications [36]. In a study done in our lab, hBD2
expression was increased after stimulation with CST, the proteolytic cleavage product of
CgA. Appreciating this, it is likely that CgA is modulating the release of hBD2 during
UTI, as also indicated by the dampened DEFB4B expression during CHGA silencing.
Additionally, CgA may also modulate cytokine release as indicated by the qPCR results
for TNF. During infection, TNF is a cytokine that stimulates the pro-inflammatory
response. If uncontrolled, over or underproduction of TNF can have adverse effects on
the body and host defense. Understanding the relationship between CgA and TNF
during a UTI can help researchers further characterize the immune response pathway.
Overall, CgA is definitely modulating host defense in some way and further studies need
to be done to investigate this interaction.
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Decreased CFU/ml in

uro-CHGA-/-

Mice

Preliminary results demonstrated increased bacterial load in CHGA-/- mice, which
prompted the necessity for a tissue-specific knockout in the bladder. Therefore, uroCHGA-/- mice were developed to knockout CgA production in uroplakin II (UPKII)containing cells of the bladder urothelium. It would be expected that in the depletion of
CgA and thus depletion of its proteolytic cleavage products, UPEC would have
increased survival. This is not what was demonstrated here. When CHGA was depleted
from UPKII, bacterial load decreased. This phenomenon was replicated with the same
results.
It is important to note that CgA could still be produced in other cell types. Based
on the role of CST in the negative feedback loop with CgA, I posit the possibility of
altered CST production as a result of decreased CgA presence. In order to maintain
host defense, CST may not fulfill its role in the negative feedback loop in an attempt to
compensate for decreased CST levels in the environment. This could leave CST open
for AMP activity or macrophage recruitment instead. The increased AMP activity may
account for the decreased bacterial burden. Further studies to investigate the levels of
CST under the murine model of UTI would be necessary to understand this relationship.
Future Directions
The Immune Response
Although the data provided is compelling, it does not tell the full story. One main
question we were striving to answer is, “how does CHGA modulate the immune
response?” We believe fluorescence-activated cell sorting (FACS) would be an effective
way to answer this question. We were able to run pilot FACS studies under the murine
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model of UTI. Unfortunately, due to low cell collection, the data was unusable here. Our
antibody panel stained and sorted for CD45+ (leukocytes), CD11c+ (dendritic cells), Ly6G+ (neutrophils), F4/80 (macrophages), CD3+ (T cells), and NK1.1 (natural killer
cells). Additionally, because our UPEC strain was GFP+, we also sorted for GFP+ cells.
This panel would provide insight into the quantity of immune cells recruited to the
bladder between mouse strains, and would also allow for us to quantify the number of
phagocytosed bacteria (GFP+Ly-6G+ cells and GFP+F4/80+ cells). When the innate
immune response is activated, immune cell recruitment becomes an essential piece of
host defense. Understanding the difference between immune cell recruitment in uroCHGA-/- and WT would further demonstrate how CgA interacts with invading microbes
in the urinary tract.
Characterization of the uro-CHGA-/- Urothelium
To better visualize the state of the urothelium in uro-CHGA-/- mice, electron
microscopy (EM) and TUNEL staining can be used. EM allows for assessment of
urothelial sloughing and exfoliation, while also providing a clear picture of bacterial
invasion [47]. As bacteria invades the urothelium, cells undergo apoptosis and start to
slough away. Apoptosis can be identified using a TUNEL stain. This would demonstrate
apoptosis occurring after infection and could be used to compare uro-CHGA-/- to WT
and Cre-. Both of these procedures are underway, but unfortunately were not complete
for this document. The images obtained from EM and TUNEL stain could further help
characterize the uro-CHGA-/- phenotype and aid in the overall understanding of CgA’s
mechanism during cystitis.
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Concluding Remarks
Overall, urinary tract infections are a significant healthcare burden, especially in
women. Understanding the mechanism of infection or the pathway of the innate immune
system is crucial in solving the antibiotic crisis. CgA does play a role in this interaction
and hopefully future studies can be conducted to further explore the relationship
between AMP, CgA, and the urothelium in hopes of finding better prevention markers
and/or treatment methods.
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